CLLS Cellectis

  1. Stocks
  2. Healthcare
  3. NASDAQ: CLLS

Price (delayed)

$1.44

Market cap

$104.69M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

$173.38M

?
Relative Growth: Rel. Growth: 24
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 31

Cellectis, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors for the treatment of cancers. Its lead product candidate is UCART19, an engineered T-cell product candidate for ...

Highlights
The company's debt fell by 8% YoY and by 4% QoQ
CLLS's net income is down by 11% year-on-year but it is up by 2.8% since the previous quarter
The company's EPS fell by 4.9% YoY but it rose by 4.5% QoQ
CLLS's equity has dropped by 58% year-on-year and by 31% since the previous quarter
The company's gross profit fell by 15% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cellectis.com
Peers: QURE NVAX REGN

Key stats

What are the main financial stats of CLLS

CLLS stock price

How has the Cellectis stock price performed over time
Intraday
-7.69%
1 week
4.73%
1 month
-57.71%
1 year
-58.74%
YTD
-70.25%
QTD
-52%

Financial performance

How have Cellectis's revenue and profit performed over time
Revenue
$63.82M
Gross profit
$63.82M
Operating income
-$58M
Net income
-$65.31M
Gross margin
100%
Net margin
-102.3%
Cellectis's operating margin has plunged by 55% from the previous quarter and by 27% YoY
The company's operating income fell by 32% QoQ and by 28% YoY
The company's gross profit fell by 15% QoQ
The revenue is down by 15% from the previous quarter

Price vs fundamentals

How does CLLS's price correlate with its fundamentals

Growth

What is Cellectis's growth rate over time

Valuation

What is Cellectis stock price valuation
P/E
N/A
P/B
2.55
P/S
2.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.72
The company's EPS fell by 4.9% YoY but it rose by 4.5% QoQ
The P/B is 62% more than the 5-year quarterly average of 1.7 but 29% less than the last 4 quarters average of 3.9
CLLS's equity has dropped by 58% year-on-year and by 31% since the previous quarter
The price to sales (P/S) is 74% lower than the 5-year quarterly average of 9.3 and 44% lower than the last 4 quarters average of 4.4
The revenue is down by 15% from the previous quarter

Efficiency

How efficient is Cellectis business performance
The company's return on sales has shrunk by 197% YoY and by 69% QoQ
CLLS's return on invested capital has dropped by 155% year-on-year and by 49% since the previous quarter
The return on equity has dropped by 89% year-on-year and by 17% since the previous quarter
CLLS's ROA is down by 35% year-on-year and by 3.9% since the previous quarter

Dividends

What is CLLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLLS.

Financial health

How did Cellectis financials performed over time
CLLS's total assets is 18% greater than its total liabilities
CLLS's total assets is down by 24% year-on-year and by 8% since the previous quarter
Cellectis's total liabilities has decreased by 12% YoY
The company's debt is 154% higher than its equity
CLLS's debt to equity has soared by 117% year-on-year and by 40% since the previous quarter
CLLS's equity has dropped by 58% year-on-year and by 31% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.